- Home
- SWVL vs RNXT Comparison
SWVL vs RNXT Comparison
Compare SWVL & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWVL
- RNXT
- Stock Information
- Founded
- SWVL 2017
- RNXT 2012
- Country
- SWVL United Arab Emirates
- RNXT United States
- Employees
- SWVL N/A
- RNXT N/A
- Industry
- SWVL Business Services
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- SWVL Consumer Discretionary
- RNXT Health Care
- Exchange
- SWVL Nasdaq
- RNXT Nasdaq
- Market Cap
- SWVL 44.5M
- RNXT 44.6M
- IPO Year
- SWVL N/A
- RNXT 2021
- Fundamental
- Price
- SWVL $4.15
- RNXT $1.27
- Analyst Decision
- SWVL
- RNXT Strong Buy
- Analyst Count
- SWVL 0
- RNXT 2
- Target Price
- SWVL N/A
- RNXT $7.25
- AVG Volume (30 Days)
- SWVL 6.1K
- RNXT 157.7K
- Earning Date
- SWVL 07-07-2025
- RNXT 08-12-2025
- Dividend Yield
- SWVL N/A
- RNXT N/A
- EPS Growth
- SWVL N/A
- RNXT N/A
- EPS
- SWVL N/A
- RNXT N/A
- Revenue
- SWVL $17,207,362.00
- RNXT $240,000.00
- Revenue This Year
- SWVL N/A
- RNXT $3,186.05
- Revenue Next Year
- SWVL N/A
- RNXT $291.93
- P/E Ratio
- SWVL N/A
- RNXT N/A
- Revenue Growth
- SWVL N/A
- RNXT N/A
- 52 Week Low
- SWVL $2.40
- RNXT $0.75
- 52 Week High
- SWVL $8.05
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- SWVL 45.93
- RNXT 45.57
- Support Level
- SWVL $3.80
- RNXT $1.27
- Resistance Level
- SWVL $4.48
- RNXT $1.42
- Average True Range (ATR)
- SWVL 0.38
- RNXT 0.06
- MACD
- SWVL -0.05
- RNXT -0.02
- Stochastic Oscillator
- SWVL 42.17
- RNXT 6.25
About SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.